Home › Alzheimer's Disease › NCT06052163
Bumetanide in Patients With Alzheimer's Disease
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
Who can join
Ages 50 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Mild cognitive impairment or mild dementia due to Alzheimer's disease. * Alzheimer's disease medications are planned to remain stable throughout. * Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI. Exclusion Criteria: * Clinically significant abnormalities in screening laboratory tests * Chronic liver disease * Renal insufficiency * Poorly managed hypertension * Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
About the study
This study aims to investigate bumetanide in patients with biologically confirmed Alzheimer's disease (AD). Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension. Repurposing bumetanide as a medication for AD has been proposed based on data that demonstrated its ability to "flip" the APOE genotype-dependent transcriptomic signatures in AD mouse and cell culture models. Critically, this discovery was subsequently explored in Electronic Health Record cohorts, which revealed that among individuals over the age of 65, bumetanide exposure was significantly associated with a lower prevalence of AD in three independent datasets.
Primary Objective: To evaluate the safety and tolerability of bumetanide when administered to participants with biomarker-confirmed Alzheimer's disease.
Secondary Objective: To evaluate the clinical and biomarker effects of bumetanide in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease.
What is being tested
- Bumetanide (drug)
- Placebo (drug)
Sponsor: Stanford University · Participants: 40 · Started: Apr 10, 2023
Contact the study team
- Mina L Kim · Phone: (650) 387-1559
Official record on ClinicalTrials.gov — NCT06052163
Locations in the U.S.
| California | Stanford University, Stanford |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.